Literature DB >> 11397508

Exploring the role of the 5'-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives.

C Chamorro1, M J Pérez-Pérez, F Rodríguez-Barrios, F Gago, E De Clercq, J Balzarini, A San-Félix, M J Camarasa.   

Abstract

Various analogues of the anti-HIV-1 agent TSAO-T, [1-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]thymine]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) have been synthesized in which the 5'-TBDMS group has been replaced by alkyl-, alkenyl- or aromatic ether groups, substituted amines, carbamoyl or (thio)acyl groups. The compounds synthesized were evaluated for their inhibitory effect on HIV-1 and HIV-2 replication in cell culture. Replacement of the 5'-TBDMS group by an acyl, aromatic or a cyclic moiety markedly diminish or even eliminate the anti-HIV activity. However, the presence at that position of an alkyl or alkenyl chain, partially retain antiviral activity. These observations suggest that the 5'-TBDMS group of the TSAO molecule plays a crucial role.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397508     DOI: 10.1016/s0166-3542(01)00145-0

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  2 in total

1.  Crystal structure of tert-butyldimethylsilyl-spiroaminooxathioledioxide-thymine (TSAO-T) in complex with HIV-1 reverse transcriptase (RT) redefines the elastic limits of the non-nucleoside inhibitor-binding pocket.

Authors:  Kalyan Das; Joseph D Bauman; Angela S Rim; Chhaya Dharia; Arthur D Clark; María-José Camarasa; Jan Balzarini; Eddy Arnold
Journal:  J Med Chem       Date:  2011-03-29       Impact factor: 7.446

2.  Synthesis and Cytostatic Effect of 3'-deoxy-3'-C-Sulfanylmethyl Nucleoside Derivatives with d-xylo Configuration.

Authors:  Miklós Bege; Alexandra Kiss; Máté Kicsák; Ilona Bereczki; Viktória Baksa; Gábor Király; Gábor Szemán-Nagy; M Zsuzsa Szigeti; Pál Herczegh; Anikó Borbás
Journal:  Molecules       Date:  2019-06-10       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.